Pharmafile Logo
Pharmafocus logo
Advanced Search

BMS

Showing 15 posts of 285 posts found.

opdivo_1_1

BMS left red-faced as Opdivo+Yervoy fails to beat rival Pfizer drug in kidney cancer

August 16, 2017
Research and Development BMS, Kidney cancer, Yervoy, life sciences, opdivo, pharma, pharmaceutical

Bristol-Myers Squibb has been left somewhat red-faced after its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) failed to show any …

News
original

Bristol-Myers Squibb’s $2.3 billion gamble to boost cancer pipeline

August 4, 2017
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, IFM Therapeutics, biotech, drugs, pharma, pharmaceutical

Bristol-Myers Squibb has agreed a deal to acquire IFM Therapeutics for a potential $2.3 billion. The latter is a biotech …

News
doug_manion

BMS vet joins Kleo Therapeutics as CEO

June 13, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Kleo Pharmaceutical

Kleo Pharmaceutical has moved to appoint industry veteran Doug Manion to the position of CEO. Kleo are a biotech company …

Appointment
scotland_flag

SMC reverses decision on Opdivo for kidney cancer

June 12, 2017
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, SMC, opdivo

The Scottish Medicines Consortium (SMC) has performed a U-turn on its decision regarding Opdivo (nivolumab), and will now allow patients …

News
shutterstock_273326141

BMS and Array BioPharma partner up to tackle colorectal cancer

May 30, 2017
Manufacturing and Production, Research and Development, Sales and Marketing Array Biopharma, BMS, Bristol-Myers Squibb

Bristol-Myers Squibb and Array BioPharma have announced they are to join forces as part of a new clinical research partnership …

News

England “really is not a good place” to get cancer, BMS UK General Manager says

April 24, 2017
Medical Communications, Research and Development, Sales and Marketing BMS, NICE, opdivo

Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in recommending access to …

News
opdivo_1_1

NICE turns down BMS’ Opdivo for head and neck cancer

April 11, 2017
Manufacturing and Production, Sales and Marketing BMS, NICE, opdivo

Bad news for Bristol-Myers Squibb as NICE chooses not to recommend its immunotherapy drug Opdivo (nivolumab) for use in head …

News
shutterstock_291014192

Asia-Pacific NSCLC market to more than double to $6.2bn by 2023

March 21, 2017
Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo

New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …

News
opdivo_1_1

NICE recommends against Opdivo for classical Hodgkin lymphoma

March 15, 2017
Research and Development, Sales and Marketing BMS, classical Hodgkin Lymphoma, opdivo

The National Institute of Health and Care Excellence (NICE) has released draft guidance provisionally turning down Bristol-Myers Squibb’s Opdivo (nivolumab) …

News
shutterstock_141299494

Immunotherapy: The three major treatments that are changing cancer prognoses

March 13, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq

The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …

Feature
thomas_headshot

BMS finds replacement for retiring CSO

March 9, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb

Bristol-Myers Squibb has announced the appointment of Dr. Thomas J. Lynch, Jr., to the position of Executive Vice President and …

Appointment
2000px-bristol-myers_squibb_logo

BMS temporarily expands Board with three new additions

February 23, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb

Bristol-Myers Squibb has bolstered its Board of Directors with the appointment of three Directors, a move which temporarily expands its …

Appointment
keytruda3-web

MSD aims to get the jump on BMS treating bladder cancer

February 6, 2017
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, MSD, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …

News

FDA clears Opdivo to treat most common form of bladder cancer

February 6, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …

News

BMS receives $625 million patent settlement boost from Merck

January 23, 2017
Sales and Marketing BMS, MSD, Merck, keytruda, opdivo

Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023